Ernexa Therapeutics Inc.
ERNA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000748592
No open-market purchases or sales by Ernexa Therapeutics Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $236.2K in total; no superinvestor holds it.
Other share classesERNAW
13F holders, Q4 2024
Institutional positions in Ernexa Therapeutics Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +4 vs. Q3 2024
- Shares held
- 994.4K
- +283.1K (+39.8%) vs. Q3 2024
- Total value
- $292.4K
- −$454.5K (−60.9%) vs. Q3 2024
- New holders
- 8
- 3 more added
- Sold out
- 4
- 4 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ERNA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $236.2K |
| Q1 2026 | 20 | $711.4K |
| Q4 2025 | 14 | $627.1K |
| Q3 2025 | 14 | $566.0K |
| Q2 2025 | 12 | $91.7K |
| Q1 2025 | 27 | $264.2K |
| Q4 2024 | 24 | $292.4K |
| Q3 2024 | 20 | $746.9K |
| Q2 2024 | 20 | $712.4K |
| Q1 2024 | 23 | $981.1K |
| Q4 2023 | 20 | $636.9K |
| Q3 2023 | 22 | $728.4K |
| Q2 2023 | 20 | $750.2K |
| Q1 2023 | 21 | $1.14M |
| Q4 2022 | 20 | $1.19M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Ernexa Therapeutics Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 10 | $3 | 0.00% | +10 | New |
| Citigroup Inc | 15 | $4 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 19 | $6 | 0.00% | 00.0% | Unchanged |
| Activest Wealth Management | 50 | $15 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 59 | $17 | 0.00% | +45+321.4% | Added |
| BNP Paribas Arbitrage, SA | 140 | $41 | 0.00% | +140 | New |
| Montag A & Associates Inc | 212 | $63 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 295 | $87 | 0.00% | +172+139.8% | Added |
| one8zero8, LLC | 10,873 | $3.20K | 0.00% | +10,873 | New |
| Goldman Sachs Group Inc | 12,813 | $3.77K | 0.00% | +12,813 | New |
| Avidian Wealth Solutions, LLC | 14,798 | $4.35K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 14,919 | $4.39K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 16,857 | $4.96K | 0.00% | −66,763−79.8% | Reduced |
| Cubist Systematic Strategies, LLC | 21,365 | $6.28K | 0.00% | +21,365 | New |
| Vanguard Group Inc | 26,099 | $7.67K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 29,736 | $8.74K | 0.00% | −3,124−9.5% | Reduced |
| Susquehanna International Group, LLP | 31,167 | $9.16K | 0.00% | +31,167 | New |
| Millennium Management LLC | 45,046 | $13.2K | 0.00% | +45,046 | New |
| Naviter Wealth, LLC | 47,271 | $13.9K | 0.00% | −31,525−40.0% | Reduced |
| Sippican Capital Advisors | 50,000 | $14.7K | 0.01% | −18,504−27.0% | Reduced |
| XTX Topco Ltd | 58,102 | $17.1K | 0.00% | +58,102 | New |
| Cypress Point Wealth Management, LLC | 94,375 | $27.7K | 0.01% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 257,310 | $75.7K | 0.00% | +236,875+1,159.2% | Added |
| CI Private Wealth, LLC | 262,862 | $77.3K | 0.00% | 00.0% | Unchanged |
| Baldwin Brothers Inc | 0 | $0 | 0.00% | −8,544−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −4,994−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Aspire Private Capital, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |